APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

Table 1 Locally advanced rectal adenocarcinoma patients analysed by gene expression microarray.

Patient	Treatment¹	Stage at Diagnosis²	Diagnostic biopsy grade & histology	Diagnostic biopsy cellularity³	Surgical biopsy grade & histology	Surgical biopsy cellularity³	Pathological stage⁴
CRT1	CRT	T2N1 M0	moderately differentiated adenocarcinoma	60%	poorly differentiated adenocarcinoma	60%	T3N2
CRT2	CRT	T3N1 M0	moderately differentiated adenocarcinoma	60%	moderately differentiated adenocarcinoma	60%	T3N1
CRT3	CRT	T3N0 M0	moderately differentiated adenocarcinoma	60%	moderately differentiated adenocarcinoma	50%	T3N0
CRT4	CRT	T4N1 M0	moderately differentiated adenocarcinoma	50%	moderately differentiated adenocarcinoma	50%	T2N0
RT1	RT	T2N0 M0	moderately differentiated adenocarcinoma	60%	moderately differentiated adenocarcinoma	60%	T3N0
RT2	RT	T2N1 M0	moderately differentiated adenocarcinoma	60%	moderately differentiated adenocarcinoma	60%	T2N1
RT3	RT	T2N0 M0	moderately differentiated adenocarcinoma	50%	moderately differentiated adenocarcinoma	60%	T3N2
RT4	RT	T2N0 M0	moderately differentiated adenocarcinoma	60%	moderately differentiated adenocarcinoma	60%	T3N0
CON1	None	T3N1 M0	moderately differentiated adenocarcinoma	75%	moderately differentiated adenocarcinoma	70%	T3N1
CON2	None	T2N1 M0	moderately differentiated adenocarcinoma	50%	moderately differentiated adenocarcinoma	50%	T3N1

¹ CRT = neoadjuvant concurrent chemoradiotherapy; RT = Short course pre-operative radiotherapy. ² MRI and clinical stage. ³ % Tumour versus normal cells in biopsy profiled. ⁴ Pathological stage post-preoperative therapy

ISSN: 1471-2407